Stockscreener 앱 받기
1.2057
4.37%
-0.0543
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada
Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com
Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India
Annovis Bio Receives Non-Compliance Notice from NYSE - MSN
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN
Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa
Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener
Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks
Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire
NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire
Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq
Game-Changing Phase 3 Results: Annovis Reveals Dual Breakthrough in Parkinson's and Alzheimer's Treatment - Stock Titan
Annovis Bio Inc. (ANVS) reports earnings - Quartz
Annovis Bio, Inc. SEC 10-K Report - TradingView
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times
Annovis Bio Inc. Reports Corporate Updates and Financial Results for Fourth Quarter and Full Year 2024 - Nasdaq
Annovis Bio Slashes Losses by 80% as FDA Greenlights Pivotal Alzheimer's Trial - Stock Titan
Annovis Bio stock hits 52-week low at $1.55 amid sharp decline - Investing.com Australia
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewswire
Revolutionary Parkinson's Treatment: Annovis Unveils Phase III Data for Multi-Target Drug - StockTitan
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.
Atria Wealth Solutions Inc. Purchases Shares of 13,002 Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio stock hits 52-week low at $1.72 amid market challenges - Investing.com Australia
ANVS ALERTLabaton Sucharow Announces the Filing of a Securities Class Action Against Annovis Bio, Inc.; Investors Encouraged to Contact the Firm Before October 18 - ACCESS Newswire
Annovis Bio stock hits 52-week low at $1.72 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio stock hits 52-week low at $2.42 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com Australia
Annovis to Host Patients’ Live Forum on February 27, 2025 - GlobeNewswire
0.36%
0.47%
자본화:
|
볼륨(24시간):